

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Blychert et al.
Serial No. : 10/564,229
Filed : January 10, 2006
For : Solid Composition Comprising a Proton Pump Inhibitor
Examiner : TBA
Group Art Unit : TBA

I hereby certify that this paper is being
electronically transmitted to the United States Postal
Service on the date indicated below.

Andrew Fessak 48,528

Agent Name PTO Reg. No.

Andrew Fessak 11/15/06

Signature

Date of Signature

Mail Stop PCT
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
under 37 C.F.R. §1.97(b)(3)

Sir:


Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3) before the mailing date of the first Office Action on the merits and, therefore, no fee should be due. However, if any fee is required, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: Nov. 15, 2006

Respectfully submitted,



Andrew Fessak
Reg. No. 48,528
Customer No. 007470
White & Case LLP
Direct Dial: (212) 819-8437

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/564,229</td> </tr> <tr> <td>Filing Date</td> <td>Jan. 10, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Blychert et al.</td> </tr> <tr> <td>Art Unit</td> <td>TBA</td> </tr> <tr> <td>Examiner Name</td> <td>TBA</td> </tr> <tr> <td>Attorney Docket Number</td> <td>1103326-0902</td> </tr> </table>		Application Number	10/564,229	Filing Date	Jan. 10, 2006	First Named Inventor	Blychert et al.	Art Unit	TBA	Examiner Name	TBA	Attorney Docket Number	1103326-0902
Application Number	10/564,229														
Filing Date	Jan. 10, 2006														
First Named Inventor	Blychert et al.														
Art Unit	TBA														
Examiner Name	TBA														
Attorney Docket Number	1103326-0902														
Sheet	1	of	1												

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.			T
		ANDERSSON et al., "Esomeprazole 40mg Capsules are Bioequivalent when Administered Intact or as the Contents Mixed with Applesauce"; Clin. Drug Invest. 2001: 21(1), p. 67-71.			
		FRESTON et al., "A Novel Option in Proton Pump Inhibitor Dosing: Lansoprazole Orally Disintegrating Tablet Dispersed in Water and Administered via Nasogastric Tube"; Aliment. Pharmacol. Ther. 2004; 20, p. 407-411.			
		WHITE et al., "Delivery of Esomeprazole Magnesium Enteric-Coated Pellets Through Small Caliber and Standard Nasogastric Tubes and Gastrostomy Tubes in Vitro"; Am. J. Health-Syst. Pharm., vol. 59, Nov. 1, 2002, p. 2085-2088.			
		DEVLIN et al., "Proton Pump Inhibitor Formulary Considerations in the Acutely Ill, Part I: Pharmacology, Pharmacodynamics, and Available Formulations"; The Annals of Pharmacotherapy, vol. 39, Oct. 2005, p. 1667-1677.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is to requirements with MPEP 807. Draw the through citation if not in conformance and not considered. Include copy of file from with any communication to applicant. *Applicant's answer citation designation number (optional). See Class Code of USPTO Patent Documents at www.uspto.gov or MPEP 806.04. *Three Office that issued the document, by the two-letter code (NPO) Standard 37.3. *For Japanese patent documents, the indication of the year of the grant of the Japanese must precede the serial number of the patent document. *Kind of document by the appropriate symbol as indicated on the document under "NPO Standard 37.3 (if possible)". *Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a search or a search by the USPTO in process; an applicant. Confidentiality is provided by 37 CFR 1.122 and 37 CFR 1.14. This collection is intended to be a source to complete this form online. *Applicant is required to submit this form to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 5450, Alexandria, VA 22313-5450.